GlaxoSmithKline Biologicals and GlycoVaxyn agreed to use the latter's bioconjugation technology to develop novel bacterial vaccines. The deal, which covers a set of pathogen targets, gives GSK an exclusive licensing option. GSK will give GlycoVaxyn an upfront payment and equity investment plus milestone fees and royalties.
GSK, GlycoVaxyn collaborate on bacterial vaccine development
SmartBrief Job Listings for Health Care
|Compliance and Ethics Director||
Sysmex America, Inc.
|Director, Site Quality Management||
|Palm Springs, CA|
|Compliance Officer-Medical Products||
W. L. Gore